Literature DB >> 21717474

Outcome of contemporary percutaneous coronary intervention in the elderly and the very elderly: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Michael P Thomas1, Mauro Moscucci, Dean E Smith, Herb Aronow, David Share, Phillip Kraft, Hitinder S Gurm.   

Abstract

BACKGROUND: There is a paucity of data on the outcome of contemporary percutaneous coronary intervention (PCI) in the elderly. Accordingly, we assessed the impact of age on outcome of a large cohort of patients undergoing PCI in a regional collaborative registry. HYPOTHESIS: Increasing age is associated with a higher incidence of procedural-related complications.
METHODS: We evaluated the outcome of 152,373 patients who underwent PCI from 2003 to 2008 in the 31 hospitals participating in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. The procedural outcomes of the cohort were compared by dividing patients into < 70 years of age, 70 to 79 years, 80 to 84 years, 85 to 89 years, and ≥ 90 years.
RESULTS: Of the cohort, 64.64% were <70 years of age, 23.83% were 70 to 79 years, 7.85% were 80 to 84 years, 3.09% were 85 to 89 years, and 0.58% were 90 years or older. Increasing age was associated with an increase in all-cause in-hospital mortality, contrast-induced nephropathy, transfusion, stroke/transient ischemic attack, and vascular complications. The overall in-hospital mortality rate was 1.09% and increased from 0.67% in those younger than 70 years up to 5.44% in those 90 years old or greater. The mortality rate in patients over 80 years approached 12% to 15% for those with ST-segment myocardial infarction and 39% in cardiogenic shock patients.
CONCLUSIONS: The proportion of elderly patients referred for PCI is increasing. Procedural complications increase with age, and patients presenting with unstable symptoms are at the highest risk.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21717474      PMCID: PMC6652312          DOI: 10.1002/clc.20926

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  A Newly Defined CHA2DS2-VA Score for Predicting Obstructive Coronary Artery Disease in Patients with Atrial Fibrillation-A Cross-Sectional Study of Older Persons Referred for Elective Coronary Angiography.

Authors:  Zyta Beata Wojszel; Łukasz Kuźma; Ewelina Rogalska; Anna Kurasz; Sławomir Dobrzycki; Bożena Sobkowicz; Anna Tomaszuk-Kazberuk
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

2.  Incidence and risk of developing contrast-induced acute kidney injury following intravascular contrast administration in elderly patients.

Authors:  Wei Song; Tuo Zhang; Jun Pu; Linghong Shen; Ben He
Journal:  Clin Interv Aging       Date:  2013-12-31       Impact factor: 4.458

3.  Outcomes of percutaneous coronary intervention in patients ≥ 75 years: one-center study in a Chinese patient group.

Authors:  Peng-Fei Chen; Dan-Ning Wang; Kan Chen; Chun Liang; Yu-Sheng Reng; Jing Yang; Ru Ding; Jacob Blackwell; De-Ning Liao
Journal:  J Geriatr Cardiol       Date:  2015-11       Impact factor: 3.327

4.  Clinical outcomes of elderly South-East Asian patients in primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Jieli Tong; Wen Wei Xiang; An Shing Ang; Wen Jun Sim; Kien Hong Quah; David Foo; Paul Jau Lueng Ong; Hee Hwa Ho
Journal:  J Geriatr Cardiol       Date:  2016-10       Impact factor: 3.327

5.  Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality.

Authors:  Salim Bary Barywani; Shijun Li; Maria Lindh; Josefin Ekelund; Max Petzold; Per Albertsson; Lars H Lund; Michael Lx Fu
Journal:  Clin Interv Aging       Date:  2015-09-28       Impact factor: 4.458

6.  Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus.

Authors:  Zhenhong Fu; Hao Xue; Jun Guo; Lian Chen; Wei Dong; Luyue Gai; Hongbin Liu; Zhijun Sun; Yundai Chen
Journal:  Cardiovasc Diabetol       Date:  2013-11-01       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.